Derivatives of (R)-2-amino-5-methoxytetralin: Antagonists and inverse agonists at the dopamine D(2A) receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 15, 1999, Pages 2167-2172

  Höök, Berit Backlund ^a   Brege, Cecilia ^a   Linnanen, Tero ^a   Mikaels, Åsa ^b   Malmberg, Åsa ^b   Johansson, Anette M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Astra Arcus AB ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(BENZYL)PROPYLAMINO] 5 METHOXYTETRALIN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS;

DOPAMINE ANTAGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR RADIOISOTOPES; TETRAHYDRONAPHTHALENES;

EID: 0033517047     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00345-5     Document Type: Article

References (19)

1. Hacksell, U.; Johansson, A.M.; Karlén, A.; Svensson, K.; Grol, C.J. In "Chirality and Biological Activity", Eds. H. Frank, B. Holmstedt, and B. Testa, Alan R. Liss, Inc., N.Y., 1989, pp 247-266.
2. Wikström, H. Prog. Med. Chem. 1992, 29, 185-216.
3. Malmberg, Å.; Nordvall, G.; Johansson, A.M.; Mohell, N.; Hacksell, U. Mol. Pharmacol. 1994, 46, 299-312.
4. Malmberg, Å.; N. Mohell, Backlund Höök, B.; Johansson, A.M.; Hacksell, U.; Nordvall, G. Eur. J. Pharmacol. 1998, 346, 299-307.
5. Karlsson, A.; Björk, L.; Pettersson, C.; Andén, N.-E.; Hacksell, U. Chirality, 1990, 2, 90-95.
6. Malmberg, Å.; Backlund Höök, B.; Johansson, A.M.; Hacksell, U. J. Med. Chem. 1996, 39, 4421-4429.
7. Ward, D.E.; Rhee, C.K. Tetrahedron Lett. 1991, 32, 7165-7166. The (S)-Mosher acid (Fluka, no 65369) had a stereochemical purity of ≥99 %ee.
8. Malmberg, Å.; Jackson, D.M.; Eriksson, A.; Mohell, N. Mol. Pharmacol. 1993, 43, 749-754.
9. Malmberg, Å. and Mohell, N.; J. Pharmacol. Exp. Ther. 1995, 274, 790-797.
10. a) De Lean, A.; Stadel, J.M.; Lefkowitz, R.J. J. Biol. Chem. 1980, 255, 7108-7117,
11. b) Kent, R.S.; De Lean, A.; Lefkowitz, R.J. Mol. Pharmacol. 1980, 17, 14-23,
12. c) Freedman, S.B.; Harley, E.A.; Iversen, L.L. Br. J. Pharmacol. 1988, 93, 437-445,
13. d) Lahti, R.A.; Figur, L.M.; Piercey, M.F.; Ruppel, P.L.; Evans, D.L. Mol.Pharmacol. 1992, 42, 432-438.
14. a) Lazareno, S.; Farries, T.; Birdsall, N.J.M. Life Sci. 1993, 52, 449-456,
15. b) Wieland, T.; Jakobs, K.H. In Heterotrimeric G Proteins; Iyengar, R., Ed.; Academic Press, Inc.: San Diego, CA, 1994; pp 3-13.
16. c) Gardner, B.; Strange, P.G. Biochem. Soc. Trans. 1995, 23, 91S.
17. a) Hacksell, U.; Svensson, U.; Nilsson, J.L.G.; Hjorth, S.; Carlsson, A.; Wikström, H.; Lindberg, P.; Sanchez, D.; J. Med. Chem. 1979, 22, 1469-1475.
18. McDermed, J.D.; McKenzie, G.M.; Freeman, H.S. J. Med. Chem. 1976, 19, 547-549.
19. Malmberg, Å.; Mikaels, Å.; Mohell, N. J. Pharmacol. Exp. Ther. 1998, 285, 119-126.